Cargando…
Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience
Dupilumab is an anti-interleukin-4 receptor monoclonal antibody that was recently approved for the treatment of atopic dermatitis (AD). In this single-center retrospective study, clinical baseline data of 117 severe AD patients treated with dupilumab were collected. At baseline and at weeks 4 and 16...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141229/ https://www.ncbi.nlm.nih.gov/pubmed/32183179 http://dx.doi.org/10.3390/jcm9030791 |
_version_ | 1783519151303688192 |
---|---|
author | Ferrucci, Silvia Casazza, Giovanni Angileri, Luisa Tavecchio, Simona Germiniasi, Francesca Berti, Emilio Marzano, Angelo Valerio Genovese, Giovanni |
author_facet | Ferrucci, Silvia Casazza, Giovanni Angileri, Luisa Tavecchio, Simona Germiniasi, Francesca Berti, Emilio Marzano, Angelo Valerio Genovese, Giovanni |
author_sort | Ferrucci, Silvia |
collection | PubMed |
description | Dupilumab is an anti-interleukin-4 receptor monoclonal antibody that was recently approved for the treatment of atopic dermatitis (AD). In this single-center retrospective study, clinical baseline data of 117 severe AD patients treated with dupilumab were collected. At baseline and at weeks 4 and 16, disease severity was assessed through the Eczema Area and Severity Index (EASI) and quality of life through the Dermatology Life Quality Index (DLQI) questionnaire, Patient-Oriented Eczema Measure (POEM), Hospital Anxiety and Depression Scale (HADS), Peak Pruritus Numerical Rating Scale (NRS-itch), and VAS-sleep. Response to dupilumab was defined as an improvement of ≥75% in EASI from baseline (EASI75). At multivariate analysis, AD onset before 18 years [OR, 2.9; 95% CI, 1.2–7.2; p = 0.0207] and absence of hypereosinophilia [OR, 2.24; 95% CI, 1.03–4.86; p = 0.0412] were identified as significant predictive parameters for response to dupilumab in terms of EASI75 at week 4 but not at week 16. Significant reductions in EASI, DLQI, POEM, HADS, NRS-itch, and VAS-sleep were found between week 4 versus baseline (p < 0.0001 for all) and week 16 versus baseline (p < 0.0001 for all). Early AD onset and absence of hypereosinophilia may be suggested as predictive markers of early response to dupilumab. We confirmed the efficacy and safety of this agent along with the improvement of life quality in severe AD patients. |
format | Online Article Text |
id | pubmed-7141229 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71412292020-04-10 Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience Ferrucci, Silvia Casazza, Giovanni Angileri, Luisa Tavecchio, Simona Germiniasi, Francesca Berti, Emilio Marzano, Angelo Valerio Genovese, Giovanni J Clin Med Article Dupilumab is an anti-interleukin-4 receptor monoclonal antibody that was recently approved for the treatment of atopic dermatitis (AD). In this single-center retrospective study, clinical baseline data of 117 severe AD patients treated with dupilumab were collected. At baseline and at weeks 4 and 16, disease severity was assessed through the Eczema Area and Severity Index (EASI) and quality of life through the Dermatology Life Quality Index (DLQI) questionnaire, Patient-Oriented Eczema Measure (POEM), Hospital Anxiety and Depression Scale (HADS), Peak Pruritus Numerical Rating Scale (NRS-itch), and VAS-sleep. Response to dupilumab was defined as an improvement of ≥75% in EASI from baseline (EASI75). At multivariate analysis, AD onset before 18 years [OR, 2.9; 95% CI, 1.2–7.2; p = 0.0207] and absence of hypereosinophilia [OR, 2.24; 95% CI, 1.03–4.86; p = 0.0412] were identified as significant predictive parameters for response to dupilumab in terms of EASI75 at week 4 but not at week 16. Significant reductions in EASI, DLQI, POEM, HADS, NRS-itch, and VAS-sleep were found between week 4 versus baseline (p < 0.0001 for all) and week 16 versus baseline (p < 0.0001 for all). Early AD onset and absence of hypereosinophilia may be suggested as predictive markers of early response to dupilumab. We confirmed the efficacy and safety of this agent along with the improvement of life quality in severe AD patients. MDPI 2020-03-13 /pmc/articles/PMC7141229/ /pubmed/32183179 http://dx.doi.org/10.3390/jcm9030791 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ferrucci, Silvia Casazza, Giovanni Angileri, Luisa Tavecchio, Simona Germiniasi, Francesca Berti, Emilio Marzano, Angelo Valerio Genovese, Giovanni Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience |
title | Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience |
title_full | Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience |
title_fullStr | Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience |
title_full_unstemmed | Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience |
title_short | Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience |
title_sort | clinical response and quality of life in patients with severe atopic dermatitis treated with dupilumab: a single-center real-life experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141229/ https://www.ncbi.nlm.nih.gov/pubmed/32183179 http://dx.doi.org/10.3390/jcm9030791 |
work_keys_str_mv | AT ferruccisilvia clinicalresponseandqualityoflifeinpatientswithsevereatopicdermatitistreatedwithdupilumabasinglecenterreallifeexperience AT casazzagiovanni clinicalresponseandqualityoflifeinpatientswithsevereatopicdermatitistreatedwithdupilumabasinglecenterreallifeexperience AT angileriluisa clinicalresponseandqualityoflifeinpatientswithsevereatopicdermatitistreatedwithdupilumabasinglecenterreallifeexperience AT tavecchiosimona clinicalresponseandqualityoflifeinpatientswithsevereatopicdermatitistreatedwithdupilumabasinglecenterreallifeexperience AT germiniasifrancesca clinicalresponseandqualityoflifeinpatientswithsevereatopicdermatitistreatedwithdupilumabasinglecenterreallifeexperience AT bertiemilio clinicalresponseandqualityoflifeinpatientswithsevereatopicdermatitistreatedwithdupilumabasinglecenterreallifeexperience AT marzanoangelovalerio clinicalresponseandqualityoflifeinpatientswithsevereatopicdermatitistreatedwithdupilumabasinglecenterreallifeexperience AT genovesegiovanni clinicalresponseandqualityoflifeinpatientswithsevereatopicdermatitistreatedwithdupilumabasinglecenterreallifeexperience |